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http://dx.doi.org/10.1016/j.ccr.2014.04.021SUMMARYSonic hedgehog (Shh), a soluble ligand overexpressed by neoplastic cells in pancreatic ductal adenocarci-
noma (PDAC), drives formation of a fibroblast-rich desmoplastic stroma. To better understand its role in
malignant progression, we deleted Shh in a well-defined mouse model of PDAC. As predicted, Shh-deficient
tumors had reduced stromal content. Surprisingly, such tumors were more aggressive and exhibited undif-
ferentiated histology, increased vascularity, and heightened proliferation—features that were fully recapitu-
lated in control mice treated with a Smoothened inhibitor. Furthermore, administration of VEGFR blocking
antibody selectively improved survival of Shh-deficient tumors, indicating that Hedgehog-driven stroma sup-
presses tumor growth in part by restraining tumor angiogenesis. Together, these data demonstrate that
some components of the tumor stroma can act to restrain tumor growth.INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is notable for its
profuse desmoplastic stroma comprised of activated fibro-
blasts, leukocytes, and extracellular matrix (Olive et al., 2009;
Theunissen and de Sauvage, 2009). Studies utilizing in vitro
assays and transplantation models have concluded that
various stromal elements can enhance cancer cell prolifera-Significance
Numerous therapies are being developed based on the premis
invasion while simultaneously limiting the delivery of chemoth
frompancreatic tumors—through genetic or pharmacological t
histology, increased vascularity and proliferation, and reduced
Smoothened inhibitors, an antistromal therapy, in pancreatic
tumors exhibit an increased sensitivity to VEGFR inhibition. B
well-vascularized, in contrast to most pancreatic cancers, our
to angiogenesis inhibitors.tion and invasion (Hwang et al., 2008; Ikenaga et al., 2010;
Lonardo et al., 2012; Vonlaufen et al., 2008; Xu et al.,
2010). Various stromal cells can also contribute to immune
suppression, further supporting tumor survival and growth.
Together, these observations have led to the paradigm that
tumor stroma functions to support and promote the growth of
cancer (Hanahan and Weinberg, 2011). Based on this para-
digm, the concept of ‘‘antistromal’’ therapy has emerged as ae that tumor stroma functions to promote cancer growth and
erapy. Here, we demonstrate that depletion of stromal cells
argeting of the Hh pathway—results in a poorly differentiated
survival. The study thus provides insight into the failure of
cancer clinical trials. Moreover, we report that Hh-deficient
ecause poorly differentiated human pancreatic tumors are
results suggest that this patient subset may be susceptible
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Figure 1. Sonic Hedgehog Behaves as a
Tumor Suppressor in a Genetically Engi-
neered Mouse Model of PDAC
(A) Schematic of the ShhPKCY mouse model used
in this study, which employs the KrasG12D (K), Pdx1-
Cre (C), p53 (P), RosaYFP (Y), and Shh alleles. Cre-
mediated deletion results in simultaneous activation
ofKras, deletion of one allele of p53, and both alleles
of Shh and recombination of the YFP lineage label.
(B) Confirmation of Shh knockdown in ShhPKCY
animals. Quantitative PCR analysis of Hedgehog
signaling components in YFP+ sorted pancreatic
epithelial derived cells and F4/80+ cells from tumors
as well as whole tumor derived from PKCY (blue)
and ShhPKCY (red) mice (n = 5 for each group; bars
represent means ± SD).
(C) Kaplan-Meier survival analysis for PKCY (n = 26)
and ShhPKCY mice (n = 23). p < 0.005 by Mantel-
Cox (log rank) test.
(D) Survival of mice from first clinical palpation of
tumor. Presence of tumor was confirmed by ultra-
sound. Bars represent means ± SD; p < 0.001.
(E) Fraction of mice with any macrometastatic lesion
by visual inspection at the time of tissue harvest by
genotype (n = 26 and 23 for PKCY and ShhPKCY
mice, respectively). p = 0.039.
(F) Quantitation of acinar to ductal metaplasia (bar A)
and PanIN lesions by grade (bars 1–3) in 8-week-old
PKCY and ShhPKCY mice. Eighty nonoverlapping
high powered fields in which pancreas tissue
covered at least 90% of the entire field were
analyzed (n = 3 for each group).
Data are presented as the aggregate number of
ADMs and PanINs (by grade) for each genotype.
#, p < 0.05; *, p < 0.01; **, p < 0.001 by two-tailed
Student’s t test. See also Figure S1.
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2012).
The Hedgehog (Hh) signaling pathway contributes to stromal
desmoplasia in multiple solid tumor systems. Although normally
absent in the adult pancreas, this developmental morphogen
pathway is reactivated during inflammation and neoplasia.
Both sonic hedgehog (Shh) ligand and downstream signaling
are induced de novo in preneoplastic lesions and increase signif-
icantly during PDAC progression as the stromal compartment
enlarges (Thayer et al., 2003). Although ectopic activation of
Hh signaling within pancreatic epithelial cells can accelerate
tumorigenesis (Mao et al., 2006; Morton et al., 2007; Pasca di
Magliano et al., 2006), deletion of the Hh signaling mediator
Smoothened (Smo) from the epithelium has no impact on
PDAC progression (Nolan-Stevaux et al., 2009). Hence, canoni-
cal Hh signaling in PDAC is likely to occur in a paracrine fashion,
whereby Shh ligand secreted from epithelial cells activates Smo-
dependent downstream signaling in adjacent stromal cells, pro-
moting desmoplasia (Bailey et al., 2008; Tian et al., 2009). The
notion that Hh-dependent tumor stroma facilitates tumorigen-
esis is supported by the finding that inhibiting Hh signaling re-
tards pancreatic tumor growth and metastasis in transplantation
models (Bailey et al., 2008; Feldmann et al., 2008a, 2008b) and
through our own study of the effects of acute inhibition of Smo
in genetically engineered mouse models (Olive et al., 2009). In
this study, we sought to interrogate the role of the tumor stroma736 Cancer Cell 25, 735–747, June 16, 2014 ª2014 Elsevier Inc.by using both genetic deletion and long-term pharmacologic in-
hibition to eliminate stroma-promoting Hh signaling.
RESULTS
Shh Loss Accelerates PDAC Progression
To explore the role of paracrine Hh signaling in an autochthonous
mouse model of PDAC, we conditionally deleted Shh, the pre-
dominant Hh ligand expressed in the diseased pancreas, by
breeding Shhfl alleles into the Pdx1-Cre;KrasLSL-G12D/+;p53fl/+;
Rosa26LSL-YFP/+ (PKCY) model (Rhim et al., 2012). Because
Pdx1-Cre mediates recombination exclusively in the epithelial
cells of the pancreas (Rhim et al., 2012), this combination of
alleles results in the simultaneous activation of mutant Kras
and deletion of Shh and p53within this tissue compartment (Fig-
ure 1A). Shh deletion had no effect on pancreatic development
(Figure S1A available online), and the resulting Shhfl/fl;Pdx1-
Cre;KrasLSL-G12D/+;p53fl/+;Rosa26LSL-YFP (ShhPKCY) mice were
born at expected Mendelian ratios and were phenotypically
normal at birth.
To confirm the deletion of Shh in the pancreatic epithelial
compartment, we performed transcriptional analysis on FACS-
sorted yellow fluorescent protein (YFP+) cells from 10- to 16-
week-old PKCY and ShhPKCY mice (Rhim et al., 2012). As
predicted, Shh transcripts were markedly reduced in YFP+
pancreatic epithelial cells from ShhPKCY mice (Figure 1B).
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Sonic Hedgehog-Dependent Stroma Suppresses PDACInterestingly, this decrease in Shh transcription was accompa-
nied by a 10-fold increase in the expression of Indian hedgehog
(Ihh), another Hh ligand, although absolute levels of Ihh remained
significantly lower than Shh. Desert hedgehog was undetectable
under all conditions (data not shown). We then determined the
impact of Shh deletion on signaling within the stromal compart-
ment by measuring the expression of the Hh target genes Ptch1
and Gli1 in sorted PDAC-associated F4/80+ monocytes and
whole pancreas, as previously described (El-Zaatari et al.,
2013). Although Ptch1 expression was similar, transcript levels
for Gli1 were significantly decreased in ShhPKCY samples as
compared to PKCY samples, indicating that overall Hh signaling
was reduced following Shh deletion (Figure 1B).
Given the important role of Shh in promoting the desmoplastic
stroma of PDAC, we expected that Shh loss would impair tumor-
igenesis. Surprisingly, however, pancreatic tumors arose in both
PKCY and ShhPKCY mice, demonstrating that Shh is dispens-
able for tumorigenesis. Remarkably, ShhPKCY mice developed
tumors earlier and had a significantly decreased survival
compared to PKCY mice (p < 0.001 by log rank [Mantel-Cox]
test; Figure 1C). Specifically, ShhPKCY mice had a median
survival of 3.61 ± 1.97 months as compared to a median
survival of 6.17 ± 2.65 months for PKCY mice (Figure S1B). Het-
erozygous Shhfl/+;Pdx-Cre; KrasLSL-G12D/+;p53fl/+;Rosa26LSL-YFP
(Shhfl/+PKCY) mice that retained one copy of Shh also had
reduced median survival compared to PKCY mice (4.14 ±
1.57 months, p = 0.004; Figure S1B). ShhPKCY tumors were
more aggressive than PKCY tumors, because mean survival
from first detection of tumor was significantly shorter in
ShhPKCYmice (19.2 ± 5.27 versus 6.5 ± 2.7 days, p < 0.001; Fig-
ure 1D), and the frequency of gross metastasis was higher in
ShhPKCY mice than in PKCY mice (43.4 versus 15.3%, p =
0.039 by chi-squared test; Figure 1E), although the tissue distri-
bution of macrometastases was similar (Figure S1C). Moreover,
histological analysis revealed a higher frequency of acinar-to-
ductal metaplasia (ADM) and pancreatic intraepithelial neoplasia
(PanIN) of all grades in 8-week-old ShhPKCY compared to PKCY
mice (Figure 1F). These data indicate that Shh is not merely
dispensable for pancreatic tumorigenesis, but that it somehow
restrains tumor progression and aggressiveness.
Shh Loss Is Associated with Changes in Stromal
Composition
Next, we compared the histology of ShhPKCY and PKCY
tumors. In contrast to thewell-differentiated tomoderately differ-
entiated histology of most PKCY tumors, ShhPKCY tumors
exhibited predominantly undifferentiated and poorly differenti-
ated histology, with few of the ductal elements observed in
most PKCY and human pancreatic tumors (Figures 2A and 2B;
Figure S2A). ShhPKCY tumors also exhibited a significant in-
crease in Zeb1 and Slug expression, two markers of epithelial-
to-mesenchymal transition, consistent with the predominance
of poorly differentiated and undifferentiated histology (Singh
et al., 2009; Watanabe et al., 2009) (Figure S2B; p < 0.05).
Using the YFP lineage label to distinguish epithelial-derived
cancer cells from mesenchyme-derived stromal cells, we found
that Shh-deficient tumors had significantly reduced stroma, as
indicated by decreased numbers of YFP-negative alpha smooth
muscle actin (SMA)-positive myofibroblasts (3.7% ± 0.7%versus 16.7% ± 3.2% of all DAPI+ cells within pancreas tumors;
p = 0.016; Figures 2C and 2D). Despite their increased aggres-
siveness (but consistent with stromal loss), ShhPKCY tumors
exhibited a trend toward decreased weight (Figure S1B). In addi-
tion, ShhPKCY tumors had fewer CD45+ myeloid cells (4.9% ±
0.9% versus 36.7% ± 5.2%; p = 0.0039; Figures 2E and 2F)
and F4/80+ monocytes (2.8% ± 0.5% versus 15.5% ± 2.7%;
p = 0.010; Figures 2G and 2H). Indeed, the stromal cell compo-
sition of ShhPKCY tumors was similar to that of normal pancreas
tissue from Pdx1-Cre;Rosa26LSL-YFP/+ mice (data not shown).
These results demonstrate that robust tumor formation can
occur in the absence of a fibroblast- and leukocyte-rich desmo-
plastic stroma.
Because ShhPKCY tumors progressed more rapidly than their
PKCY counterparts, we hypothesized that parallel but opposite
changes in tumor vasculature might influence tumor growth.
Hence, we examined the endothelial compartment in tumors
with and without Shh by CD31 staining. Consistent with this hy-
pothesis, ShhPKCY tumors exhibited a substantial increase in
the number of blood vessels within the tumor (32.4 ± 7.2 versus
11.2 ± 3.8 CD31+ vessels per high powered field; p = 0.0004;
Figures 3A and 3B). In addition, the autofluorescent drug doxo-
rubicin was delivered more effectively to ShhPKCY tumors, sug-
gesting that increased vascular density was accompanied by
greater perfusion (Figures 3C and 3D). To assess whether this in-
crease in vasculature was associated with changes in autophagy
or proliferation, we stained for the autophagosome marker LC3
and the proliferation marker proliferating cell nuclear antigen
(PCNA). This analysis revealed a decrease in YFP+LC3+ cells in
ShhPKCY tumors (Figures 3E and 3F) and an increase in the
frequency of YFP+PCNA+ proliferating tumor cells (Figures 3G
and 3H). These data therefore suggest that undifferentiated
ShhPKCY tumors are better perfused than PKCY tumors, a
change that was associated with enhanced nutrient delivery,
decreased autophagy, and increased proliferation.
Chronic Smoothened Inhibition Phenocopies Shh
Deletion
We next sought to learn whether the effect of Shh deletion in
pancreatic cancer is mediated by canonical Hh signaling. We uti-
lized IPI-926 (Infinity Pharmaceuticals), a targeted inhibitor of
Smo, to inhibit canonical Hh signaling in KPC mice (a PDAC
model closely related to the PKCY model). We previously per-
formed a preclinical evaluation of IPI-926 in KPC mice harboring
large (6–9 mm) pancreatic tumors and found that the combina-
tion of IPI-926 and the nucleoside analog gemcitabine (gem) re-
sulted in extension of overall survival (Olive et al., 2009), a finding
at odds with the observed effect of genetic Shh deletion. We
reasoned that long-term, chronic exposure to Smo inhibition
might unveil indirect responses related to the depletion of stroma
from tumors rather than the acute response to improved drug
delivery. Therefore, we treated KPC mice with IPI-926 alone or
vehicle beginning at 8 weeks of age, a time point at which
ADM and PanIN lesions are present but at which mice have
not yet developed tumors (Figure S3A; see Supplemental Exper-
imental Procedures for additional details).
Strikingly, IPI-926-treated KPC mice exhibited a reduction in
overall survival compared to vehicle-treated mice (121 versus
156 days, p < 0.0001 by log rank test; Figure 4A). This resultCancer Cell 25, 735–747, June 16, 2014 ª2014 Elsevier Inc. 737
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Figure 2. Loss of Shh Leads to a Shift in
Pancreatic Tumor Histopathology
(A and B) H&E staining showing representative
histology from PKCY (A) and ShhPKCY (B) tumors.
Insets show higher magnified view of sections
marked by the box.
(C–H) Multicolor immunofluorescence images of
PKCY (left column) and ShhPKCY tumors
(right column) assessed for myofibroblasts (C and
D), total leukocytes (E and F), or macrophages
(G and H).
(C and D) Fluorescent images showing staining
with the pancreas epithelial lineage label YFP
(green) and the myofibroblast marker alpha-SMA
(red). Inset, quantitation of SMA+ cells as a per-
centage of all nucleated (DAPI+) cells within PKCY
(blue) and ShhPKCY (red) tumors (n = 3–5; #, p =
0.016; bars represent means ± SD).
(E and F) Fluorescent images showing staining
with YFP (green) and the pan-leukocyte marker
CD45 (red). Inset, quantitation of CD45+ cells as
a percentage of all nucleated (DAPI+) cells (n =
3–5; *, p = 0.0039; bars represent means ± SD).
(G and H) Fluorescent images showing staining
with YFP (green) and the macrophage marker
F4/80 (red). Inset, quantitation of F4/80+ cells as
a percentage of all nucleated (DAPI+) cells (n =
3–5; #, p = 0.010; bars represent means ± SD).
Scale bars, 40 mm for main panels and 20 mm for
insets. See also Figure S2.
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vention study (Olive et al., 2009), despite the fact that the model,
drug, dose, route, and schedule were all identical. In an effort to
replicate this result and also determinewhether coadministration
of gemcitabine might change the dynamics of tumor response,
we treated a separate cohort of mice with the combination of
gemcitabine + IPI-926 or gemcitabine + vehicle. As shown in Fig-
ure 4B, the addition of gemcitabine provided a minor extension
of survival over IPI-926 monotherapy (p = 0.01, log rank), but
the IPI-926-gem combination therapy still resulted in shortened
survival compared to vehicle-treated mice from the previous
cohort. These results suggest that any benefit afforded by
improved drug availability following Smo inhibition is outweighed
by other effects on tumor biology in the chronic setting.738 Cancer Cell 25, 735–747, June 16, 2014 ª2014 Elsevier Inc.Analysis of 3D high resolution ultra-
sound data (Sastra and Olive, 2013)
demonstrated that KPC mice treated
with IPI-926 or IPI-926-gemcitabine suc-
cumbed more rapidly following initial
tumor detection (Figure 4C) and that
tumor size was significantly smaller at
sacrifice (Figure 4D), similar to the
reduced tumor weight observed in
ShhPKCY mice (Figure S1B). Indeed,
several mice met endpoint criteria before
it was possible to detect tumors in their
pancreas by ultrasound. However, all
but one of these mice was found to
have tumors upon careful histopatholog-
ical analysis. There was no difference inthe age at which tumors developed between the two groups,
suggesting that IPI-926 treatment accelerates tumor progres-
sion after initiation without reducing latency (Figure 4E). Com-
plete tumor volume data for these mice are presented in Figures
4F and 4G.
To better understand why IPI-926-treatedmice with very small
tumors were dying, we performed detailed necropsies on each
mouse and assigned a ‘‘proximal cause of death’’ to each
animal. Vehicle- or gem-treated KPC mice typically succumbed
to the consequences of locally destructive disease (e.g., local
invasion into the gut or abdominal hemorrhage) or high metasta-
tic burden, with only a small subset exhibiting severe weight
loss. By contrast, nearly all of the IPI-926-treated mice were
euthanized following a period of rapid and severe weight loss
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Figure 3. Shh Deletion Results in Greater
Vascular Density and Proliferation within
Pancreatic Tumors
(A and B) Blood vessel density in PKCY and
ShhPKCY tumors was determined by staining for
the endothelial marker CD31 (red) and the tumor
cell lineage marker YFP (green). Inset, measure-
ment of mean vascular density (MVD) within PKCY
(blue) and ShhPKCY (red) tumors (quantified as
number of CD31+ vessels per high powered field;
n = 3–5; *, p = 0.004; bars represent means ± SD).
No Tx, no treatment.
(C and D) Cellular perfusion in PKCY and
ShhPKCY tumors was determined by intravas-
cular delivery of the autofluorescent drug doxoru-
bicin. The inset in C shows fluorescence of a liver
section from the same PKCY mouse (positive
control). The inset in D shows fluorescence of a
ShhPKCY tumor injected with PBS (negative
control).
(E and F) Autophagy in PKCY and ShhPKCY
tumors was determined by staining for the auto-
phagosomal protein LC3 (red). Inset, percentage
of LC3+ cells within the YFP+ tumor cell popula-
tion in PKCY (blue) and ShhPKCY (red) tumors
(n = 3–5; #, p = 0.002; bars represent means ± SD).
(G and H) Proliferation in PKCY and ShhPKCY
tumors was determined by staining for the cell
cycle marker PCNA (red). Inset, percentage of
PCNA+ cells within the YFP+ tumor cell popula-
tion in PKCY (blue) and ShhPKCY (red) tumors
(n = 3–5; *, p = 0.004; bars represent means ± SD).
Scale bars, 40 mm.
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ShhPKCY animals (data not shown).
The tumors arising in IPI-926-treated mice were more poorly
differentiated than those arising in controls treated with vehicle
or gem alone (Figures 5A–5F), consistent with the observation
that ShhPKCY mice developed poorly differentiated tumors. It
is worth highlighting a pair of noteworthy exceptions that empha-
size the relationship between differentiation state and tumor
progression: one IPI-926-treated tumor was extremely well-
differentiated and progressed slowly, whereas one vehicle-
treated mouse succumbed at an early time point from a
small tumor that was 50% poorly differentiated (Figure 4F,
highlighted). Examination of pancreatic tissues adjacent to
the tumors revealed an exceptionally high content of ADMsCancer Cell 25, 735–7and PanINs in IPI-926-treated mice (Fig-
ures S4A–S4D). This feature was not
shared in IPI-926+gemcitabine-treated
mice, possibly because of the impact of
genotoxic chemotherapy on the pro-
liferation of preneoplastic lesions. Immu-
nohistochemical analyses revealed that
IPI-926-treated tumors were more highly
proliferative (Figure 5G; Figures S4E–
S4H) and had increased vascular content
(Figure 5H; Figures S4I–S4L). Together,
these data demonstrate that pharmaco-
logic inhibition of canonical Hedgehogsignaling accelerates tumor growth, phenocopying the effect of
genetic deletion of Shh in pancreatic tumors.
HedgehogSignaling Acts in aParacrine Fashion inPDAC
During embryonic endoderm development, Hedgehog ligand is
secreted by gut epithelial cells and acts on adjacent mesen-
chymal cells to pattern the submucosal layers of the gut (Roberts
et al., 1998; Sukegawa et al., 2000). Given strong evidence from
previous literature that Hedgehog signaling acts in a paracrine
fashion during pancreatic carcinogenesis (Bailey et al., 2008;
Tian et al., 2009), we sought to determine whether a similar
signaling relay was operating in the autochthonous models. To
this end, we introduced a Gli1GFP reporter (Brownell et al.,
2011) into the KPC background and assessed the distribution47, June 16, 2014 ª2014 Elsevier Inc. 739
Figure 4. Smoothened Inhibition Acceler-
ates Pancreatic Tumor Development
(A–G) Two separate cohorts of KPC mice were
treated with vehicle (VEH) versus IPI-926 (926), or
gemcitabine (GEM) versus IPI-926 + gemcitabine
(926/GEM), beginning at 8 weeks of age, as
described in Supplemental Experimental Pro-
cedures. High resolution 3D ultrasound was used
to monitor tumor development and to quantify
tumor volumes. Treatment continued until mice
met endpoint criteria.
(A) Kaplan-Meier curve showing IPI-926 treated
KPC mice (red, n = 12), vehicle-treated KPC mice
(blue, n = 12) (p < 0.0001, log rank test, vehicle
versus IPI-926), and an historical collection of un-
treated KPC mice (gray, n = 165) (p < 0.0001, log
rank test, historical cohort versus IPI-926).
(B) Kaplan-Meier curve showing IPI-926 + gemci-
tabine-treated KPCmice (red, n = 11) and vehicle +
gemcitabine-treated KPC mice (blue, n = 12) (p <
0.004, log rank test, gemcitabine + vehicle versus
gemcitabine + IPI-926). The data from panel A are
overlaid in gray (p = 0.01, log rank test, IPI-926
versus IPI-926 + gemcitabine).
(C) Graph of time from first detection of tumor (by
3D ultrasound) to death in animals among the four
treatment groups, comparing animals that received
IPI-926 to those that did not (p = 0.0003 in mono-
therapy group, p = 0.006 in combination group).
Animals with microscopic tumors on necropsy but
no measurable tumor on ultrasound were included
as 0 days. The data are presented as standard box
and whisker plots.
(D) Final tumor volumes (measured by 3D ultra-
sound) among the four treatment groups, com-
paring animals that received IPI-926 to those that
did not (p = 0.0026 in monotherapy group, p =
0.012 in the combination group). Several IPI-926-
treated mice met endpoint criteria prior to the
detection of tumors by ultrasound and are included
as 0 mm3. The data are presented as standard box
and whisker plots.
(E) Age of tumor detection (by 3D ultrasound)
among the four treatment groups (p = 0.17 for
monotherapy, p = 0.48 for combination). The
data are presented as standard box and whisker
plots.
(F) Graph showing tumor volumes of mice treated
with IPI-926 (red) or vehicle (blue) plotted versus
the mouse’s age in days. Two exceptional tumors
noted in the text are highlighted in yellow.
(G) Graph showing tumor volumes of mice treated with gemcitabine + IPI-926 (red) or gemcitabine + vehicle (blue) are plotted versus the mouse’s age in days.
Lethal tumors that were undetectable by ultrasoundwere assigned a volume of 0 on the day of death. Animals still alive at the time of submission are denoted with
open diamonds.
See also Figure S3.
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Sonic Hedgehog-Dependent Stroma Suppresses PDACof GFP+ cells in the resulting KPC-Gli1GFP mice by immunofluo-
rescence. GFP staining was readily observed in the E-cadherin-
negative (stromal) portions of KPC-Gli1GFP mice but was absent
from E-cadherin-positive (epithelial) cells (Figures 6A and 6B).
Consistent with this observation, spheroid formation of a KPC
pancreatic tumor cell line was unaffected by treatment with re-
combinant Shh protein or IPI-926 (Figure S5A). In contrast,
nearly all alpha-SMA+ myofibroblasts were found to be Gli1GFP
positive, indicating active Hh pathway signaling in this mesen-
chymally derived cell type (Figures 6A and 6C). This is consistent740 Cancer Cell 25, 735–747, June 16, 2014 ª2014 Elsevier Inc.with previous reports demonstrating a proliferative effect from
Hh pathway signaling in fibroblasts (Walter et al., 2010). How-
ever, further examination of these tissue sections revealed that
many Gli1GFP-positive cells (43%) were alpha-SMA negative
(Figures 6A and 6C), indicating that multiple stromal cell types
can respond to Hh signaling. Importantly, treatment of KPC-
Gli1GFP mice with IPI-926 for 10 days completely abrogated
GFP staining, indicating that GFP staining was accurately report-
ing canonical Hedgehog signaling (Figures 6D and 6E). Taken
together, these experiments confirm that canonical Hh signaling
Figure 5. Long-Term Smoothened Inhibi-
tion Yields Poorly Differentiated Pancreatic
Tumors with Increased Proliferation and
Vascularity
(A–D) Representative histology (hematoxylin and
eosin stain) of KPC tumors arising after long-term
treatment with vehicle (A, VEH), IPI-926 (B),
gemcitabine + vehicle (C), or gemcitabine + IPI-
926 (D).
(E and F) Quantification of the differentiation state
for each cohort. The fraction of each tumor
that was observed to be well-differentiated (W),
moderately differentiated (M), poorly differentiated
(P), or undifferentiated (U) was scored in a blinded
manner, and compared between the treatments.
No tumor could be located in one IPI-926 + gem-
citabine-treated mouse (N).
(G) Quantification of phospho-histone H3+ cells
per 40[times] field in each treatment group (p =
0.034 for monotherapy, p = 0.011 for combina-
tion). The data are presented as standard box and
whisker plots.
(H) Quantification of CD31+ vessel structures by
IHC in each treatment cohort (p = 0.004 for mon-
otherapy, p < 0.0001 for combination). The data
are presented as standard box and whisker plots.
Two-tailed Mann-Whitney U tests were used for
all unpaired tests. Scale bars, 50 mm. See also
Figure S4.
Cancer Cell
Sonic Hedgehog-Dependent Stroma Suppresses PDACoperates in a paracrine fashion in PDAC, as it does during em-
bryonic development.
Shh-Deficient Tumors Are Sensitive to VEGF Inhibition
We next investigated the surprising increase in vasculature in
ShhPKCYmice and in IPI-926-treated KPCmice.We first sought
to determine whether increased angiogenesis was a direct result
of reduced Hh pathway signaling in endothelial cells. We
performed coimmunofluorescence on untreated KPC-Gli1GFP
mice for GFP and the endothelial marker endomucin but found
that Hh pathway signaling is absent in nearly all tumor endothelial
cells (Figures 6A and 6F). Consistent with this observation,Cancer Cell 25, 735–7capillary sprouting of cultured human
umbilical venous endothelial cells was
unaffected by exposure to recombinant
Shh or IPI-926 (Figure S5B). These results
suggest that the proangiogenic effect of
Hh pathway inhibition is mediated indi-
rectly by signals from mesenchyme-
derived stromal cells.
VEGF is a well-known soluble angio-
genic factor. As a group, mouse and
human PDAC are unaffected by treat-
ment with VEGF receptor inhibitors,
consistent with their poor vascularization
(Singh et al., 2010). However, undifferen-
tiated tumors comprise approximately
5%–10% of all advanced PDAC (Iacobu-
zio-Donahue et al., 2009). We hypothe-
sized that the higher vessel density and
paucity of stroma of undifferentiatedtumors might render them sensitive to angiogenesis inhibitors.
To test this hypothesis, we treated tumor-bearing ShhPKCY
and control PKCYmice with DC101, a blocking antibody against
VEGFR2. Similar to previous studies (Singh et al., 2010), VEGFR
inhibition had little effect on tumor size or survival in PKCY mice
(Figure 7A; Figure S6A). However, treatment of ShhPKCY mice
with DC101 led to significantly improved overall survival com-
pared to treatment with Ig control (median survival 22.4 versus
12.5 days from enrollment; p = 0.028; Figure 7B). DC101 treat-
ment was associated with the appearance of large areas of
necrosis on hematoxylin and eosin (H&E) (Figures 7C and 7D),
and immunofluorescence staining demonstrated a reduced47, June 16, 2014 ª2014 Elsevier Inc. 741
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Figure 6. Hh Pathway Activity Is Restricted
to Mesenchymally Derived Stromal Cells
(A) Quantification of coimmunofluorescence (Co-
IF) for the Gli1GFP Hh reporter and markers of
various tumor and stromal populations.
(B) Co-IF for Gli1GFP (green) and E-Cadherin (red,
E-Cad) in KPC-Gli1GFP tumors.
(C) Co-IF for Gli1GFP (green) and alpha-SMA (red,
aSMA) in in KPC-Gli1GFP tumors. White arrow de-
notes an alpha-SMA+, Gli1+ cell. Yellow arrow de-
notes an alpha-SMA, Gli1+ cell. Orange arrow
denotes an aSMA+, Gli1 cell.
(D and E) Co-IF for Gli1GFP reporter on an untreated
KPC-Gli1GFP tumor (D) or after 10 days of IPI-926
treatment (E).
(F) Co-IF for Gli1GFP (green) and the endothelial
marker endomucin (red, Endo) in KPC-Gli1GFP
tumors. Arrow denotes a Gli1 endothelial cell.
Scale bars, 10 mm. See also Figure S5.
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S6C), an increase in the percentage of tumor cells with LC3+
autophagosomes (Figure 7F; Figures S6D and S6E), and
reduced proliferation (Figure 7G; Figures S6F and S6G) in
DC101-treated ShhPKCY mice. Interestingly, there was no dif-
ference in tumor VEGF expression between ShhPCKY versus
PKCY mice or between IPI-926- versus vehicle-treated KPC
tumors (data not shown). Thus, the depletion of Hh-dependent
stroma from pancreatic tumors leads to a greater utilization
and dependence on existing VEGF-mediated angiogenic path-
ways rather than a de novo induction of VEGF ligand.
Finally, we examined human pancreatic tumors to determine
whether similar relationships between histology, Hedgehog
signaling, and vascularity were present. In a set of 225 prospec-
tively collected and analyzed human PDAC, undifferentiated
tumors had significantly less Gli1 expression compared to all
other tumors with well, moderately, and poorly differentiated
histology (1.42 versus 2.99; p = 0.0102 by Student’s t test,742 Cancer Cell 25, 735–747, June 16, 2014 ª2014 Elsevier Inc.two-tailed; Figure S6H). However, no
statistically significant difference was de-
tected in Shh expression. Thus, undiffer-
entiated human PDACmay be associated
with attenuated canonical Hedgehog
signaling, as predicted by our studies
of genetically engineered mice. In a
separate, independently collected and
analyzed set of human PDAC, we exam-
ined 13 total human pancreatic tumors
stratified into differentiated (n = 5) and
undifferentiated (n = 8) histology to deter-
mine whether differentiation status corre-
lated with vessel density in patients.
Similar to mice, undifferentiated human
pancreatic tumors exhibited significantly
greater vascular density and less stroma
compared to differentiated tumors, even
when both components were present
within the same primary carcinoma (Fig-
ures 7H–7J). Surprisingly, undifferentiatedPDAC had a similar vascular density as normal human pancreas
tissue (Figure 7J). These data indicate that like murine ShhPKCY
tumors, undifferentiated pancreatic tumors in patients also have
a more prominent vasculature.
DISCUSSION
Nearly 50 years have passed since Stoker’s pioneering studies
of epithelial/stromal interactions in cancer demonstrated that
normal fibroblasts restrain the growth of transformed baby
hamster kidney cells (Stoker et al., 1966). This ‘‘neighbor sup-
pression’’ effect may be part of an evolved microenvironment
surveillance against the development of preneoplasia (Klein,
2014). Nevertheless, in the context of established tumors,
the prevailing paradigm of the tumor microenvironment field
has been that tumor stroma supports, rather than inhibits,
neoplastic growth and progression (Hanahan and Weinberg,
2011). This concept has been bolstered by work on pancreatic
Cancer Cell
Sonic Hedgehog-Dependent Stroma Suppresses PDACtumors, which are associated with a particularly dense ‘‘desmo-
plastic’’ stroma. Such studies, which have mostly relied on cell
transplantation or in vitro assays, have affirmed that the stroma
plays a supportive role in of pancreatic cancer progression
(Bailey et al., 2008; Feldmann et al., 2008a, 2008b; Hwang
et al., 2008; Ikenaga et al., 2010; Lonardo et al., 2012; Xu
et al., 2010). In this study, we have examined the effects of per-
turbing the tumor microenvironment by genetically deleting
sonic hedgehog or pharmacologically inhibiting its essential
signaling mediator Smoothened. These interventions greatly
reduced stromal desmoplasia, but such tumors unexpectedly
exhibited accelerated tumor growth, increased systemic
morbidity, and increased metastasis, ultimately leading to earlier
mortality. Thus, our findings demonstrate that at least some stro-
mal constituents can act to restrain, rather than promote, tumor
progression.
We previously reported that acute administration of IPI-926 to
KPC mice bearing large tumors leads to stromal collapse and
increased vascularity, consistent with the results shown here
(Olive et al., 2009). In that study, treatment with Smo inhibitor
alone had minimal effects on tumor size or survival, whereas
combined treatment with the Smo inhibitor and gemcitabine
led to transient stabilizations and regressions, producing a
modest survival benefit (Olive et al., 2009). These results were in-
terpreted as an indication that stromal inhibition could lead to
improved drug delivery without a direct effect on tumor growth.
However, because most animals in our previous study experi-
enced less than 3 weeks of IPI-926 treatment, there was little
opportunity to detect accelerated tumor progression in this
acute setting. Indeed, despite the success of IPI-926 in treating
basal cell carcinoma (Jimeno et al., 2013), the poor clinical per-
formance of Smo inhibitors in pancreatic cancer trials has led to
uncertainty regarding the approach of stromal targeting. Our
current data suggest that the short-term, beneficial effects of
increased drug delivery are eventually overcome by the negative
effects of long-term Smo inhibition.
What is responsible for the increase in tumor cell proliferation
and overall mortality in ShhPKCY (and IPI-926-treated) tumors?
At present, the precise mechanism for increased tumor cell
proliferation remains unknown and is likely to be complex.
Nevertheless, the nearly 3-fold increase in blood vessel density
in ShhPKCY tumors compared to PKCY tumors—an associa-
tion that has been previously observed in IPI-926-treated KPC
mice (Olive et al., 2009)—is likely to be a major contributor to
this effect. This inference is supported by the observation that
the more vascular ShhPKCY tumors had a nearly 5-fold
decrease in autophagy, a process of cellular autodigestion
used by nutrient-deprived cells (Kondo et al., 2005). Moreover,
ShhPKCY tumors exhibited a responsiveness to antiangiogenic
therapy that was absent in PKCY tumors, suggesting that the
more highly vascular Shh-deficient tumors were dependent on
this enhanced blood supply. Thus, our study suggests that
the interaction between the tumor and its microenvironment is
complex, with certain components of the microenvironment
(i.e., vasculature) having a tumor-promoting role and other com-
ponents (i.e., myofibroblasts) having an inert or tumor-suppres-
sive role.
A paradoxical result of our study was the observation that the
tumors lacking Hedgehog signaling—following either geneticablation or treatment with IPI-926—were smaller despite their
more aggressive and lethal phenotype, a finding that may reflect
the fact that the stroma normally comprises a large percentage
of PDAC tumor volume (Chu et al., 2007). Although we do not
fully understand the accelerated mortality of Shh-deficient
tumors, one possibility is suggested by the finding that tumor-
bearing animals treated with IPI-926 exhibited significantly
more weight loss and wasting prior to death than vehicle- or
gem-treated tumors. It is conceivable that stromal inhibition
(and associated changes in tumor metabolism) may lead to
increased cachexia, a wasting syndrome common in human
PDAC patients. Importantly, we do not believe that IPI-926 con-
tributes to increased mortality or wasting independent of PDAC,
because extensive clinical follow-up (Jimeno et al., 2013) and our
own observations treating tumor-free animals (data not shown)
failed to demonstrate any such toxicity.
There are several models that could account for the finding
that ShhPKCY tumors have a reduction in myofibroblasts and
leukocytes and an increase in blood vessels. Our data demon-
strate that Hh signaling is nearly absent in the endothelial popu-
lation, arguing against a direct role in angiogenesis. Rather, our
findings are consistent with a model in which mesenchymal
stromal cells exert an antiangiogenic effect on endothelial cells,
possibly acting either directly or indirectly to elevate interstitial
fluid pressure, which then represses blood vessel growth (Jaco-
betz et al., 2013; Provenzano et al., 2012). Importantly, these
possibilities are not mutually exclusive, and future studies will
be needed to understand the nature of cellular crosstalk be-
tween different components of the microenvironment and the
role that Shh plays in each.
It is worth noting that global deletion of Gli1, a knownmediator
of Hedgehog signaling, completely blocks the development of
KrasG12D-driven pancreatic tumors (Mills et al., 2013). However,
because Gli1 can be activated by signals other than Smooth-
ened, it is unclear whether this reported requirement for Gli1
is due to so-called ‘‘canonical’’ (Smo-mediated) Hedgehog sig-
naling or is mediated by other Gli1-dependent signaling path-
ways. Moreover, because the Gli1GFP reporter showed little if
any activity within the tumor epithelium, it is unlikely that the
effects we observed are due to a Hh-Smo-Gli1 signaling relay
within the tumor cells themselves. Importantly, we employed
autochthonous models that harbor mutant Kras and p53—muta-
tions that are present in 95% and 75%–90% of human PDAC
patients, respectively—and it remains to be determined whether
the observed effects of Hedgehog deficiency on tumor biology
occur only in the context of these genetic lesions or are more
generalizable.
It is remarkable that the genetic or pharmacologic manipula-
tion of Hedgehog signaling was associated with a dramatic
change in tumor histology, illustrating the high degree of plas-
ticity of differentiation status that exists within tumors in vivo.
These data are corroborated by our analysis of human pancre-
atic tumors. Because poorly differentiated histopathology is
strongly associated with poor outcome in PDAC (Han et al.,
2006; Yonemasu et al., 2001), this finding has potential clinical
implications. Specifically, the observation that inhibition of the
Hedgehog pathway leads to the development of less differenti-
ated andmore aggressive tumors may explain the lack of benefit
observed in clinical trials.Cancer Cell 25, 735–747, June 16, 2014 ª2014 Elsevier Inc. 743
Figure 7. VEGFR2 Antagonism Leads to Selective Inhibition of Tumor Growth in ShhPKCY Mice
(A) Kaplan-Meier survival curve for tumor-bearing PKCY mice treated with bi-weekly DC101 (purple, n = 10) or Ig control (blue, n = 11).
(B) Kaplan-Meier survival curve for tumor-bearing ShhPKCY mice treated with bi-weekly DC101 (purple, n = 13) or Ig control (red, n = 10).
(C and D) H&E analysis of ShhPKCY tumors showing a large area of necrosis upon DC101 treatment (D). Scale bars, 250 mm.
(E) Quantification of CD31+ vessel density in ShhPKCY mice treated with DC101 compared to Ig control, depicted as mean (±SD) number of CD31+ vessels per
high powered field (n = 3–5).
(F) Quantification of YFP+ cells containing LC3+ autophagosomes in ShhPKCYmice treated with DC101 compared to Ig control, depicted as percentage (±SD) of
YFP+ tumor cells exhibiting LC3 staining (n = 3–5).
(legend continued on next page)
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Sonic Hedgehog-Dependent Stroma Suppresses PDACFinally, our discovery that undifferentiated tumors were sensi-
tive to VEGFR inhibition points to a possible biomarker of sensi-
tivity to angiogenesis inhibitors in pancreatic cancer. Themarked
response of ShhPKCY tumors to an antiangiogenesis agent
suggests that such undifferentiated tumors are dependent on a
plentiful vascular network. Although clinical trials of antiangio-
genesis agents failed to show benefit in PDAC, a portion of
patients treated with bevacizumab did exhibit a durable
response (Kindler et al., 2010). Approximately 5%–10% of
advanced human pancreatic tumors exhibit an undifferentiated
histology (Iacobuzio-Donahue et al., 2009), and the data we
present here suggest that such tumors have a higher blood
vessel density. Given our finding that poorly differentiated but
well-vascularized pancreatic tumors respond to VEGF receptor
blockade, it may be worth reconsidering antiangiogenesis treat-
ment strategies for the subset of patients who harbor predomi-
nantly undifferentiated PDAC.
EXPERIMENTAL PROCEDURES
Mouse Models
All studies were conducted in compliance with the institutional guidelines of
their respective locations. Two genetically engineered mouse models were
used in these studies: p53fl/+; KrasLSL-G12D/+;Pdx1-Cre;Rosa26YFP (PKCY)
(Rhim et al., 2012) and KrasLSL-G12D/+;p53LSL-R172H;Pdx1-Cre (KPC) (Hingorani
et al., 2005). ShhPKCY and PKCY mice were used to determine the effect of
Shh deletion in tumorigenesis and cancer progression. KPC mice were used
in a chronic treatment trial of IPI-926. The Gli1eGFP/+ allele was crossed into
the KPC mouse for immunofluorescence studies (Brownell et al., 2011).
Analysis of Tumor Progression and Survival in PKCY and
ShhPKCY Mice
All experiments involving mice were performed in accordance with relevant
institutional and national guidelines and were approved by the institutional
animal care and use committees at the University of Pennsylvania, Columbia
University, and University of Michigan prior to experimentation. Starting at
2 months of age, mice were palpated twice weekly for evidence of tumor. If
a potential mass was appreciated, transabdominal ultrasound was performed
using a SonoSite M-Turbo ultrasound. If the presence of a tumor was
confirmed, mice were examined weekly using ultrasound and general physical
exam. If the mouse appeared moribund (decreased spontaneous physical
activity, decreased toe pinch reflex, tachycardia, tachypnea, failure to groom,
and ruffled coat), indicating low probability of surviving for greater than 24 hr, it
was sacrificed for analysis. The tumors were immediately removed and
weighed; the dimensions were measured; and the animals were analyzed for
evidence of macrometastatic disease.
In Vivo DC101 T1rial
Upon detection of tumor by ultrasound, ShhPKCY and PKCY mice were ran-
domized to two treatment arms: DC101 or IgG1 control (800 mg per mouse;
Bio X Cell, West Hanover, NH) administered intraperitoneally every Monday
and Thursday. Technicians were blinded to treatment group.
Analysis of Human Pancreatic Tumors
Studies involving all human pancreas tumors were approved by the institu-
tional review boards of Johns Hopkins University and Mayo School of
Medicine, and informed consent was obtained from all patients prior to tissue(G) Quantification of YFP+ cells staining with the proliferation in ShhPKCYmice trea
tumor cells that were PCNA positive (n = 3 YFP 5).
(H and I) IHC for CD31 in differentiated (H) and undifferentiated (I) portions of hu
(J)Mean vascular density of normal pancreas (n = 3), differentiated humanPDAC (n
sided Student’s t test.
See also Figure S6.procurement and subsequent analysis. Paraffin-embedded sections (4 mm
thickness) of eight human ductal adenocarcinomas with undifferentiated
features from the Johns Hopkins Gastrointestinal Rapid Medical Donation
Program (Iacobuzio-Donahue et al., 2009) were used and compared to five
conventional PDACs and three samples of normal pancreas. Immunolabeling
for CD31 was performed using standard histologic methods with prediluted
anti-human CD31 monoclonal antibody (Ventana, clone JC70) and detected
using the Dako universal liquid DAB+ substrate chromagen system per the
manufacturer’s instructions (catalog K3468). Slides were counterstained
with hematoxylin for 30 s. Microvascular density was calculated as the number
of CD31+ vessels per field using a 40[times] objective and a minimum of four
fields per sample.Statistics
All statistics, including Kaplan-Meier statistics (log rank) and results from chi-
squared tests, Mann-Whitney U tests, and Student’s t tests, were calculated
using GraphPad Prism v.5.04 or v.6. The p values from Student’s t tests are
listed unless otherwise specified. In all graphs, means (bars) and standard
deviations (lines) are denoted.SUPPLEMENTAL INFORMATION
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